Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GALR2 | O43603 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9532719 | 0.90 | POLB (0.36) | POLBGALR2LMNAMAPTALDH1A1 | |
| SCHEMBL9534040 | 0.77 | MAPT (0.40) | POLBGALR2LMNAMAPTALDH1A1 | |
| SCHEMBL9533320 | 0.76 | — | — | |
| SCHEMBL9535035 | 0.74 | CTSB (0.41) | POLBGALR2LMNAMAPTALDH1A1 | |
| SCHEMBL9534856 | 0.72 | HSP90AA1 (0.49) | POLBGALR2LMNAMAPTALDH1A1 | |
| SCHEMBL9533842 | 0.71 | TXNRD1 (0.55) | POLBGALR2LMNAMAPTALDH1A1 | |
| SCHEMBL9532539 | 0.71 | MEN1 (0.48) | POLBHSP90AA1HSP90AB1MEN1KMT2A | |
| Dnqx SCHEMBL1258964 | 0.70 | POLB (0.57) | POLBGALR2LMNAMAPTALDH1A1 | |
| SCHEMBL26231986 | 0.68 | GPR35 (0.44) | POLBLMNAMAPTALDH1A1BRD4 | |
| SCHEMBL9533717 | 0.68 | PIM1 (0.36) | POLBGALR2LMNAMAPTCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0348872-B1 | FUSED DIHYDROXYQUINOXALINES AND THEIR USE AS GLUTAMATE ANTAGONISTS | NOVO NORDISK A/S (DK) | 1993-09-29 | — | — | EP | claimed |
| US-4977155-A | Nervous system disorders | A/S FERROSAN (DK) | 1990-12-11 | — | — | US | claimed |
| EP-0348872-A1 | Fused dihydroxyquinoxalines and their use as glutamate antagonists | NOVO NORDISK A/S (DK) | 1990-01-03 | — | — | EP | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| CN-111386107-A | Use of probenecid in the treatment of an epileptic disease, disorder or condition | 巴黎科技与文学─拉丁区 | 2020-07-07 | — | — | CN | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-0348872-B1 | FUSED DIHYDROXYQUINOXALINES AND THEIR USE AS GLUTAMATE ANTAGONISTS | NOVO NORDISK A/S (DK) | 1993-09-29 | — | — | EP | disclosed |
| EP-0526543-A4 | DERIVATIVES AND ANALOGUES OF 2-DEOXY-2,3-DIDEHYDRO-N-ACETYL NEURAMINIC ACID AND THEIR USE AS ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 1993-04-21 | — | — | EP | disclosed |
| EP-0526543-A1 | DERIVATIVES AND ANALOGUES OF 2-DEOXY-2,3-DIDEHYDRO-N-ACETYL NEURAMINIC ACID AND THEIR USE AS ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 1993-02-10 | — | — | EP | disclosed |
| US-5109001-A | Treating hyperactivity of excitatory neurotransmitters | NOVO NORDISK A/S (DK) | 1992-04-28 | — | — | US | disclosed |
| US-5079250-A | TRICYCLIC HETEROCYCLIC DIOLS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-01-07 | — | — | US | disclosed |
| US-5075306-A | Nervous system, psychological disorders | NOVO NORDISK A/S (DK) | 1991-12-24 | — | — | US | disclosed |
| US-5057516-A | Nervous system disorders | NOVO NORDISK A/S (DK) | 1991-10-15 | — | — | US | disclosed |
| US-4977155-A | Nervous system disorders | A/S FERROSAN (DK) | 1990-12-11 | — | — | US | disclosed |
| EP-0348872-A1 | Fused dihydroxyquinoxalines and their use as glutamate antagonists | NOVO NORDISK A/S (DK) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | POLB 4075/4885GALR2 2264/4885LMNA 1380/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | POLB 4075/4885GALR2 2264/4885LMNA 1380/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | POLB 4075/4885GALR2 2264/4885LMNA 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.